Electrophysiologic testing of bretylium tosylate in sustained ventricular tachycardia.
We used programmed ventricular stimulation to test intravenous bretylium tosylate in 10 consecutive patients with inducible sustained ventricular tachycardia (usually refractory to type I antiarrhythmic agents). These 10 patients had previously documented sustained ventricular tachycardia and/or ventricular fibrillation complicating stable heart disease. Following control inductions of sustained ventricular tachycardia, bretylium 10 mg/kg was infused over 30 minutes. Thirty minutes after this infusion, sustained ventricular tachycardia could be induced in 9 of the 10 patients (one of these nine patients also had bretylium-potentiated spontaneous ventricular tachycardia). Tachycardia induced in the nine patients after bretylium was similar to control tachycardia with respect to morphology and cycle length (333 +/- 16 msec after bretylium versus 330 +/- 16 msec during control). However, five of the nine patients tolerated induced tachycardia less well after bretylium (exacerbated hypotension). In one patient, ventricular tachycardia could not be induced after intravenous bretylium.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001949:Bretylium Compounds / Q000008:administration & dosage*; D001950:Bretylium Tosylate / Q000008:administration & dosage*; D002304:Cardiac Pacing, Artificial; D004562:Electrocardiography; D005260:Female; D006352:Heart Ventricles; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D013610:Tachycardia / Q000175:diagnosis / Q000188:drug therapy*
D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D001950:Bretylium Tosylate